DaVita Inc. Q3 2025 Earnings Recap

DVA Q3 2025 October 30, 2025

Get alerts when DVA reports next quarter

DaVita reported a strong third quarter in 2025, achieving adjusted operating income of $517 million and adjusted earnings per share of $2.51, maintaining its trajectory for the full year.

Earnings Per Share Miss

$2.51 vs $3.17 est.

-20.8% surprise

Revenue Miss

3420227000 vs 3428486690 est.

-0.2% surprise

Market Reaction

1-Day +0.23%

5-Day +2.34%

30-Day +0.36%

See DVA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted operating income and earnings per share were consistent with internal expectations, reaffirming guidance for the year.
The company's clinical research division, DaVita Clinical Research, remains a leader in advancing kidney care, conducting over 500 clinical trials and contributing to FDA approvals.
Effective management of patient care costs, despite a 1.5% year-over-year decline in U.S. treatment volume, has supported financial stability.
Strategic investments in technology infrastructure and AI solutions are expected to enhance patient care and operational efficiency long-term.
Full-year adjusted operating income guidance narrowed to $2.035 – $2.135 billion, with earnings per share projected between $10.35 and $11.15.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit DVA on AllInvestView.

Next Q1 2026